Interactive Research And Development Global 1

1. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
2. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
3. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
4. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
5. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
6. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
7. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
8. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
9. Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
1